Abstract |
We have performed combined chemotherapy with 5-FU, a biochemical modulator, and low dose CDDP for advanced or recurrent cancer of the digestive system. The therapy was effective in 37% of all cases and in 45.5% and 41.6% of esophageal and gastric cancer cases, respectively. In addition, few patients developed adverse side effects including renal disorders, one of the major side effects of CDDP. Therefore, we considered home anti- cancer chemotherapy feasible. For 27 outpatients with advanced cancer of the digestive system including 15 cases of esophageal cancer, 4 cases of gastric cancer, 3 cases of colon cancer, 4 cases of pancreatic cancer and 1 case of gall bladder cancer, 4 to 6 week home adjuvant chemotherapy was performed. The regimen comprised 1 week of oral administration of 300 mg/body/day of UFT-E granules and 5 days of continuous intravenous infusion of 25 mg/body/day of CDDP using an infusor pump. During the follow-up, 3 cases of catheter obstruction, 3 cases of catheter sepsis and 1 case of pneumothorax appeared. These complications all resulted from the catheter, and safe home anti- cancer chemotherapy could be continued because 5-FU and CDDP did not cause severe side effects.
|
Authors | T Ogura, Y Hiramatsu, H Araki, Y Kojima, A Nakagawa, M Nakagawa, Y Kamiyama, T Shirasaka |
Journal | Gan to kagaku ryoho. Cancer & chemotherapy
(Gan To Kagaku Ryoho)
Vol. 22 Suppl 4
Pg. 433-8
(Dec 1995)
ISSN: 0385-0684 [Print] Japan |
PMID | 8849289
(Publication Type: Clinical Trial, English Abstract, Journal Article)
|
Chemical References |
- Tegafur
- Uracil
- Cisplatin
- Fluorouracil
|
Topics |
- Administration, Oral
- Ambulatory Care
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Chemotherapy, Adjuvant
- Cisplatin
(administration & dosage, adverse effects)
- Digestive System Neoplasms
(drug therapy)
- Drug Administration Schedule
- Female
- Fluorouracil
(administration & dosage, adverse effects)
- Home Care Services, Hospital-Based
- Humans
- Infusion Pumps
- Infusions, Intravenous
- Male
- Neoplasm Recurrence, Local
(drug therapy)
- Quality of Life
- Tegafur
(administration & dosage)
- Uracil
(administration & dosage)
|